GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
GO:00453339 | Cervix | CC | cellular respiration | 66/2311 | 230/18723 | 2.07e-11 | 5.39e-09 | 66 |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
GO:004578510 | Cervix | CC | positive regulation of cell adhesion | 101/2311 | 437/18723 | 1.96e-10 | 3.08e-08 | 101 |
GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
GO:00508638 | Cervix | CC | regulation of T cell activation | 80/2311 | 329/18723 | 1.28e-09 | 1.47e-07 | 80 |
GO:00060919 | Cervix | CC | generation of precursor metabolites and energy | 105/2311 | 490/18723 | 7.40e-09 | 6.61e-07 | 105 |
GO:00071598 | Cervix | CC | leukocyte cell-cell adhesion | 85/2311 | 371/18723 | 8.27e-09 | 7.07e-07 | 85 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:00071738 | Cervix | CC | epidermal growth factor receptor signaling pathway | 36/2311 | 108/18723 | 1.04e-08 | 8.44e-07 | 36 |
GO:00159809 | Cervix | CC | energy derivation by oxidation of organic compounds | 74/2311 | 318/18723 | 3.83e-08 | 2.53e-06 | 74 |
GO:011005310 | Cervix | CC | regulation of actin filament organization | 67/2311 | 278/18723 | 4.01e-08 | 2.54e-06 | 67 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0502018 | Cervix | CC | Prion disease | 98/1267 | 273/8465 | 2.64e-18 | 1.42e-16 | 8.42e-17 | 98 |
hsa0541520 | Cervix | CC | Diabetic cardiomyopathy | 76/1267 | 203/8465 | 1.40e-15 | 6.46e-14 | 3.82e-14 | 76 |
hsa0501018 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0493218 | Cervix | CC | Non-alcoholic fatty liver disease | 58/1267 | 155/8465 | 3.58e-12 | 1.05e-10 | 6.23e-11 | 58 |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0421810 | Cervix | CC | Cellular senescence | 49/1267 | 156/8465 | 1.30e-07 | 1.63e-06 | 9.61e-07 | 49 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0516620 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa0467020 | Cervix | CC | Leukocyte transendothelial migration | 36/1267 | 114/8465 | 5.22e-06 | 4.83e-05 | 2.86e-05 | 36 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PIK3CA | SNV | Missense_Mutation | rs121913273 | c.1624G>A | p.Glu542Lys | p.E542K | P42336 | protein_coding | deleterious(0.04) | probably_damaging(0.912) | TCGA-3C-AALK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
PIK3CA | SNV | Missense_Mutation | | c.3012G>T | p.Met1004Ile | p.M1004I | P42336 | protein_coding | deleterious(0.01) | benign(0.047) | TCGA-3C-AALK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
PIK3CA | SNV | Missense_Mutation | rs121913279 | c.3140A>T | p.His1047Leu | p.H1047L | P42336 | protein_coding | tolerated(0.44) | benign(0.007) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PIK3CA | SNV | Missense_Mutation | rs121913287 | c.263G>A | p.Arg88Gln | p.R88Q | P42336 | protein_coding | tolerated(0.06) | probably_damaging(0.971) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PIK3CA | SNV | Missense_Mutation | rs121913273 | c.1624G>A | p.Glu542Lys | p.E542K | P42336 | protein_coding | deleterious(0.04) | probably_damaging(0.912) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PIK3CA | SNV | Missense_Mutation | rs867262025 | c.2176N>A | p.Glu726Lys | p.E726K | P42336 | protein_coding | tolerated(0.36) | benign(0.396) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PIK3CA | SNV | Missense_Mutation | rs121913279 | c.3140N>G | p.His1047Arg | p.H1047R | P42336 | protein_coding | tolerated(0.11) | benign(0.085) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PIK3CA | SNV | Missense_Mutation | rs121913273 | c.1624N>A | p.Glu542Lys | p.E542K | P42336 | protein_coding | deleterious(0.04) | probably_damaging(0.912) | TCGA-A2-A04N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
PIK3CA | SNV | Missense_Mutation | rs121913287 | c.263N>A | p.Arg88Gln | p.R88Q | P42336 | protein_coding | tolerated(0.06) | probably_damaging(0.971) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
PIK3CA | SNV | Missense_Mutation | rs121913281 | c.3139N>T | p.His1047Tyr | p.H1047Y | P42336 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | Torkinib | | 21358673 |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | inhibitor | 249565692 | | |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | PI3K-ALPHA INHIBITOR MEN1611 | | 21558396 |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | PD-0325901 | PD-0325901 | 26272063,24339963,21325073 |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | Gemcitabine | GEMCITABINE | 28750271 |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | Deguelin | DEGUELIN | 24978597,20811676 |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | GEFITINIB | GEFITINIB | 21258250 |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | ERLOTINIB | ERLOTINIB | 21258250 |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | Dasatinib | DASATINIB | 26855149 |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | inhibitor | BAY80-6946 | COPANLISIB | |